<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB14596</drugbank-id>
  <drugbank-id>DBSALT000930</drugbank-id>
  <name>Loteprednol etabonate</name>
  <description>Loteprednol Etabonate (LE) is a topical corticoid anti-inflammatory. It is used in ophthalmic solution for the treatment of steroid responsive inflammatory conditions of the eye such as allergic conjunctivitis, uveitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and selected infective conjunctivitides. As a nasal spray, it can be used for the treatment and management of seasonal allergic rhinitis.&#13;
&#13;
Most prescription LE products, however, tend to be indicated for the treatment of post-operative inflammation and pain following ocular surgery [FDA Label]. A number of such new formulations that have been approved include Kala Pharmaceutical's Inveltys - the first twice-daily (BID) ocular corticosteroid approved for this indication, designed specifically to enhance patient compliance and simplified dosing compared to all other similar ocular steroids that are dosed four times daily [L4545].&#13;
&#13;
Moreover, LE was purposefully engineered to be a 'soft drug', one that is designed to be active locally at the site of administration and then rapidly metabolized to inactive components after eliciting its actions at the desired location, thereby subsequently minimizing the chance for adverse effects [A38693].</description>
  <cas-number>82034-46-6</cas-number>
  <unii>YEH1EZ96K6</unii>
  <average-mass>466.96</average-mass>
  <monoisotopic-mass>466.175831</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A1312</ref-id>
        <pubmed-id>18245274</pubmed-id>
        <citation>Pavesio CE, Decory HH: Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol. 2008 Apr;92(4):455-9. doi: 10.1136/bjo.2007.132621. Epub 2008 Feb 1.</citation>
      </article>
      <article>
        <ref-id>A38681</ref-id>
        <pubmed-id>28017774</pubmed-id>
        <citation>Samir A, Bodor N, Imai T: Identification of esterase involved in the metabolism of two corticosteroid soft drugs. Biochem Pharmacol. 2017 Mar 1;127:82-89. doi: 10.1016/j.bcp.2016.12.010. Epub 2016 Dec 22.</citation>
      </article>
      <article>
        <ref-id>A38682</ref-id>
        <pubmed-id>1491342</pubmed-id>
        <citation>Hochhaus G, Chen LS, Ratka A, Druzgala P, Howes J, Bodor N, Derendorf H: Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs. J Pharm Sci. 1992 Dec;81(12):1210-5.</citation>
      </article>
      <article>
        <ref-id>A38693</ref-id>
        <pubmed-id>1959381</pubmed-id>
        <citation>Druzgala P, Wu WM, Bodor N: Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr Eye Res. 1991 Oct;10(10):933-7.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L4539</ref-id>
        <title>Electronic Medicines Compendium: Loteprednol etabonate Monograph</title>
        <url>https://www.medicines.org.uk/emc/product/6212</url>
      </link>
      <link>
        <ref-id>L4545</ref-id>
        <title>Inveltys FDA Approval Press Release</title>
        <url>https://www.drugs.com/newdrugs/fda-approves-inveltys-loteprednol-etabonate-post-operative-inflammation-pain-following-ocular-4808.html?utm_source=ddc&amp;utm_medium=email&amp;utm_campaign=Today%27s+news+summary+-+August+24%2C+2018&amp;utm_content=FDA+Approves+Inveltys+%28loteprednol+etabonate%29+for+Post-Operative+Inflammation+and+Pain+Following+Ocular+Surgery</url>
      </link>
    </links>
    <attachments>
      <attachment>
        <ref-id>F1467</ref-id>
        <title>Australian Register of Therapeutic Goods: Loteprednol etabonate Product Information</title>
        <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/467/original/auspar-loteprednol-etabonate-140417-pi.docx?1536691506</url>
      </attachment>
    </attachments>
  </general-references>
  <synthesis-reference/>
  <indication>A number of prescription loteprednol etabonate ophthalmic products are specifically indicated for the treatment of post-operative inflammation and pain following ocular surgery [FDA Label]. </indication>
  <pharmacodynamics>Loteprednol etabonate (LE) belongs to a unique class of corticosteroids with potent anti-inflammatory effects designed to be active at the site of action [A1312, L4539]. Animal studies have shown that LE has a binding affinity to steroid receptors that is 4.3 times greater than dexamethasone [L4539]. This particular class of steroids consists of bioactive molecules whose in-vivo transformation to non-toxic substances can be predicted from their chemistry and knowledge of enzymatic pathways in the body [L4539]. Cortienic acid is an inactive metabolite of hydrocortisone and analogs of cortienic acid are also devoid of corticosteroid activity [L4539]. Specifically, LE is an ester derivative of one of these analogs, cortienic acid etabonate [L4539]. In particular, LE possesses a metabolically labile 17 beta-chloromethyl ester function which was designed in order to be hydrolyzed to an inactive carboxylic acid moiety [A1312]. This inactive metabolite is more hydrophilic and is thus readily eliminated from the body [A1312]. LE also exhibits good ocular permeation properties and good skin permeation properties [A1312].</pharmacodynamics>
  <mechanism-of-action>Corticosteroids like loteprednol etabonate inhibit the inflammatory response to a variety of inciting agents and likely delay or slow healing [FDA Label, L4539, A1312]. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation that are commonly associated with inflammation [FDA Label, A1312]. While glucocorticoids are known to bind to and activate the glucocorticoid receptor, the molecular mechanisms involved in glucocorticoid/glucocorticoid receptor-dependent modulation of inflammation are not clearly established [FDA Label, L4539, A1312]. Moreover, corticosteroids are thought to inhibit prostaglandin production through several independent mechanisms [FDA Label, A1312]. In particular, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins [F1467]. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid [F1467]. Arachidonic acid is released from membrane phospholipids by phospholipase A2 [F1467].  &#13;
&#13;
The use of LE subsequently treats post-operative inflammation and pain following ocular surgery by managing the prostaglandin release, recruitment and travel of neutrophils and macrophages, and production of other inflammatory mediators that are intrinsically associated with the physical trauma of surgery [A1312].</mechanism-of-action>
  <toxicity>The most common adverse drug reactions reported during clinical trials for the medication were eye pain and posterior capsular opacification, both of which may also be the consequence of the very surgical procedures performed on the eye(s) [FDA Label].&#13;
&#13;
The agent is not absorbed systemically following topical ophthalmic administration and maternal use is not expected to result in fetal exposure to the drug [FDA Label].&#13;
&#13;
The medication is not absorbed systemically by the mother following topical ophthalmic administration, and breastfeeding is not expected to result in exposure of the child to the agent [FDA Label].&#13;
&#13;
Long-term animal studies have not been conducted to evaluate the carcinogenic potential of loteprednol etabonate. Loteprednol etabonate was not genotoxic in vitro in the Ames test, the mouse lymphoma thymidine kinase (tk) assay, or in a chromosome aberration test in human lymphocytes, or in vivo in the single dose mouse micronucleus assay [FDA Label].&#13;
&#13;
Overdose is not expected to be likely to occur after ocular administration [F1467].</toxicity>
  <metabolism>Loteprednol etabonate (LE) is readily and extensively metabolized to two inactive metabolites, PJ-90 (Δ1-cortienic acid) and PJ-91 (Δ1-cortienic acid etabonate) [FDA Label, F1467].  Metabolism occurs locally in ocular tissues, and to the extent that loteprednol etabonate reaches the systemic circulation, likely the liver and other tissues into which it distributes [F1467].&#13;
&#13;
In particular, studies have demonstrated that LE (chloromethyl 17alpha-ethoxycarbonyloxy-11beta-hydroxy-3-oxoandrosta-1,4-diene) is rapidly hydrolyzed at the location of its 17beta-chloromethyl ester function by paraoxonase 1 in human plasma at the site of administration at the level of the affected eye tissue to the 17beta-carboxylate PJ-91 metabolite and PJ-90 metabolite [A38681, A38693]. Both metabolites are considered inactive [FDA Label, A38693, A38693].</metabolism>
  <absorption>Loteprednol etabonate (LE) demonstrates good ocular permeation properties as it is lipid soluble, allowing the agent to penetrate into cells with relative ease [FDA Label, A1312].&#13;
&#13;
Results from the ocular administration of loteprednol in normal, healthy volunteers have shown that there are low or undetectable concentrations of either unchanged material or its metabolite [L4539]. Following twice-daily unilateral topical ocular dosing of LE for 14 days in healthy subjects, the plasma concentrations of loteprednol etabonate were below the limit of quantitation (1 ng/mL) at all time points [FDA Label]. These finds suggest that limited, if any, systemic absorption of LE occurs [L4539].</absorption>
  <half-life>The terminal half-life of loteprednol etabonate as determined when administered intravenously at a dose of 5 mg/kg in the dog animal model is 2.8 hours [A38682].</half-life>
  <protein-binding>Strong protein binding of approximately 98% for loteprednol etabonate facilitates little pharmacodynamic action and/or adverse effects on the part of the agent in the systemic circulation [A38681].</protein-binding>
  <route-of-elimination>Following systemic administration to rats, loteprednol etabonate is eliminated primarily via the biliary/faecal route, with most of the dose eliminated in the form of the metabolite, PJ-90 [F1467].</route-of-elimination>
  <volume-of-distribution>The only data available regarding the volume of distribution of loteprednol etabonate (LE) is the volume of distribution the agent demonstrated when administered to dogs - a value of 3.7 L/kg [A38682]. It has been shown, however, that the topical ocular administration of LE distributes preferentially into the cellular components of blood [F1467].</volume-of-distribution>
  <clearance>Loteprednol etabonate was slowly hydrolyzed in liver at clearance rates of  0.21 +/- 0.04 and 2.41 +/- 0.13 ml/h/kg in the liver and plasma, respectively [A38681].</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.</description>
    <direct-parent>Steroid esters</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Lipids and lipid-like molecules</superclass>
    <class>Steroids and steroid derivatives</class>
    <subclass>Steroid esters</subclass>
    <alternative-parent>11-beta-hydroxysteroids</alternative-parent>
    <alternative-parent>3-oxo delta-1,4-steroids</alternative-parent>
    <alternative-parent>Alkyl chlorides</alternative-parent>
    <alternative-parent>Androgens and derivatives</alternative-parent>
    <alternative-parent>Carbonic acid diesters</alternative-parent>
    <alternative-parent>Carboxylic acid esters</alternative-parent>
    <alternative-parent>Cyclic alcohols and derivatives</alternative-parent>
    <alternative-parent>Cyclic ketones</alternative-parent>
    <alternative-parent>Delta-1,4-steroids</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Monocarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organochlorides</alternative-parent>
    <alternative-parent>Secondary alcohols</alternative-parent>
    <substituent>11-beta-hydroxysteroid</substituent>
    <substituent>11-hydroxysteroid</substituent>
    <substituent>3-oxo-delta-1,4-steroid</substituent>
    <substituent>3-oxosteroid</substituent>
    <substituent>Alcohol</substituent>
    <substituent>Aliphatic homopolycyclic compound</substituent>
    <substituent>Alkyl chloride</substituent>
    <substituent>Alkyl halide</substituent>
    <substituent>Androgen-skeleton</substituent>
    <substituent>Androstane-skeleton</substituent>
    <substituent>Carbonic acid derivative</substituent>
    <substituent>Carbonic acid diester</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Carboxylic acid ester</substituent>
    <substituent>Cyclic alcohol</substituent>
    <substituent>Cyclic ketone</substituent>
    <substituent>Delta-1,4-steroid</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Hydroxysteroid</substituent>
    <substituent>Ketone</substituent>
    <substituent>Monocarboxylic acid or derivatives</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organochloride</substituent>
    <substituent>Organohalogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Oxosteroid</substituent>
    <substituent>Secondary alcohol</substituent>
    <substituent>Steroid ester</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="usan">Loteprednol etabonate</synonym>
  </synonyms>
  <products>
    <product>
      <name>Alrex</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4277</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-10-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength>2 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>NDA020803</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alrex</name>
      <labeller>Stat Rx USA</labeller>
      <ndc-id/>
      <ndc-product-code>16590-007</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-03-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength>2 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>NDA020803</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alrex</name>
      <labeller>Bausch &amp; Lomb Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code>24208-353</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-03-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength>2 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>NDA020803</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alrex</name>
      <labeller>Bausch &amp; Lomb Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02320924</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength>0.2 %</strength>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Inveltys</name>
      <labeller>Kala Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71571-121</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Topical</route>
      <fda-application-number>NDA210565</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lotemax</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4278</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-10-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength>5 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>NDA020583</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lotemax</name>
      <labeller>Bausch &amp; Lomb Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code>24208-503</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>5 mg/1g</strength>
      <route>Ophthalmic</route>
      <fda-application-number>NDA202872</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lotemax</name>
      <labeller>Bausch &amp; Lomb Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code>24208-443</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-04-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength>5 mg/1g</strength>
      <route>Ophthalmic</route>
      <fda-application-number>NDA200738</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lotemax</name>
      <labeller>Bausch &amp; Lomb Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code>24208-299</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-03-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength>5 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>NDA020583</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lotemax</name>
      <labeller>Bausch &amp; Lomb Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02321114</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength>0.5 %</strength>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lotemax Gel</name>
      <labeller>Bausch &amp; Lomb Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02435853</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lotemax Ointment</name>
      <labeller>Bausch &amp; Lomb Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02421941</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lotemax SM</name>
      <labeller>Bausch &amp; Lomb Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code>24208-507</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>3.8 mg/1g</strength>
      <route>Ophthalmic</route>
      <fda-application-number>NDA208219</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Loteprednol Etabonate</name>
      <labeller>Oceanside Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68682-299</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength>5 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>NDA020583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Loteprednol Etabonate</name>
      <labeller>Hi-Tech Pharmacal Co., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50383-265</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength>5 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA207609</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zylet</name>
      <labeller>Bauch &amp; Lomb Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code>24208-358</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-12-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA050804</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Loteflam</name>
      <company>Cipla Pharmaceuticals Limited</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Lotemax</name>
      <ingredients>Loteprednol etabonate</ingredients>
    </mixture>
    <mixture>
      <name>Alrex</name>
      <ingredients>Loteprednol etabonate</ingredients>
    </mixture>
    <mixture>
      <name>Alrex</name>
      <ingredients>Loteprednol etabonate</ingredients>
    </mixture>
    <mixture>
      <name>Zylet</name>
      <ingredients>Loteprednol etabonate + Tobramycin</ingredients>
    </mixture>
    <mixture>
      <name>Inveltys</name>
      <ingredients>Loteprednol etabonate</ingredients>
    </mixture>
    <mixture>
      <name>Lotemax</name>
      <ingredients>Loteprednol etabonate</ingredients>
    </mixture>
    <mixture>
      <name>Lotemax SM</name>
      <ingredients>Loteprednol etabonate</ingredients>
    </mixture>
    <mixture>
      <name>Lotemax</name>
      <ingredients>Loteprednol etabonate</ingredients>
    </mixture>
    <mixture>
      <name>Loteprednol Etabonate</name>
      <ingredients>Loteprednol etabonate</ingredients>
    </mixture>
    <mixture>
      <name>Alrex</name>
      <ingredients>Loteprednol etabonate</ingredients>
    </mixture>
    <mixture>
      <name>Lotemax</name>
      <ingredients>Loteprednol etabonate</ingredients>
    </mixture>
    <mixture>
      <name>Loteprednol Etabonate</name>
      <ingredients>Loteprednol etabonate</ingredients>
    </mixture>
    <mixture>
      <name>Alrex</name>
      <ingredients>Loteprednol etabonate</ingredients>
    </mixture>
    <mixture>
      <name>Lotemax</name>
      <ingredients>Loteprednol etabonate</ingredients>
    </mixture>
    <mixture>
      <name>Lotemax Ointment</name>
      <ingredients>Loteprednol etabonate</ingredients>
    </mixture>
    <mixture>
      <name>Lotemax Gel</name>
      <ingredients>Loteprednol etabonate</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Alchymars SPA</name>
      <url/>
    </packager>
    <packager>
      <name>Bausch &amp; Lomb Inc.</name>
      <url>http://www.bausch.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Bausch and lomb inc</manufacturer>
    <manufacturer generic="false" url="">Pharmos corp</manufacturer>
  </manufacturers>
  <prices/>
  <categories>
    <category>
      <category>Adrenal Cortex Hormones</category>
      <mesh-id>D000305</mesh-id>
    </category>
    <category>
      <category>Androstadienes</category>
      <mesh-id>D000730</mesh-id>
    </category>
    <category>
      <category>Androstanes</category>
      <mesh-id>D000731</mesh-id>
    </category>
    <category>
      <category>Androstenes</category>
      <mesh-id>D000736</mesh-id>
    </category>
    <category>
      <category>Anti-Allergic Agents</category>
      <mesh-id>D018926</mesh-id>
    </category>
    <category>
      <category>Corticosteroids</category>
      <mesh-id>D000305</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Fused-Ring Compounds</category>
      <mesh-id>D000072473</mesh-id>
    </category>
    <category>
      <category>Immunosuppressive Agents</category>
      <mesh-id>D007166</mesh-id>
    </category>
    <category>
      <category>Steroids</category>
      <mesh-id>D013256</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Suspension</form>
      <route>Ophthalmic</route>
      <strength>0.2 %</strength>
    </dosage>
    <dosage>
      <form>Suspension / drops</form>
      <route>Ophthalmic</route>
      <strength>2 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Topical</route>
      <strength>10 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Gel</form>
      <route>Ophthalmic</route>
      <strength>5 mg/1g</strength>
    </dosage>
    <dosage>
      <form>Ointment</form>
      <route>Ophthalmic</route>
      <strength>5 mg/1g</strength>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Ophthalmic</route>
      <strength>0.5 %</strength>
    </dosage>
    <dosage>
      <form>Suspension / drops</form>
      <route>Ophthalmic</route>
      <strength>5 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Gel</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Ointment</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Gel</form>
      <route>Ophthalmic</route>
      <strength>3.8 mg/1g</strength>
    </dosage>
    <dosage>
      <form>Suspension / drops</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes>
    <ahfs-code>52:08.08</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB14596.pdf?1536686810</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB14596.pdf?1536686810</msds>
  <patents>
    <patent>
      <number>5540930</number>
      <country>United States</country>
      <approved>1996-07-30</approved>
      <expires>2013-10-25</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>4996335</number>
      <country>United States</country>
      <approved>1991-02-26</approved>
      <expires>2012-03-09</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2174550</number>
      <country>Canada</country>
      <approved>2002-10-01</approved>
      <expires>2014-10-21</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>5800807</number>
      <country>United States</country>
      <approved>1998-09-01</approved>
      <expires>2017-01-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9056057</number>
      <country>United States</country>
      <approved>2015-06-16</approved>
      <expires>2033-05-03</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9532955</number>
      <country>United States</country>
      <approved>2017-01-03</approved>
      <expires>2033-05-03</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9827191</number>
      <country>United States</country>
      <approved>2017-11-28</approved>
      <expires>2033-05-03</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>10058511</number>
      <country>United States</country>
      <approved>2018-08-28</approved>
      <expires>2033-05-03</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9737491</number>
      <country>United States</country>
      <approved>2017-08-22</approved>
      <expires>2033-05-03</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9393213</number>
      <country>United States</country>
      <approved>2016-07-19</approved>
      <expires>2033-05-03</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>Trastuzumab may increase the neutropenic activities of Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>Tacrolimus may increase the immunosuppressive activities of Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01432</drugbank-id>
      <name>Cholestyramine</name>
      <description>Cholestyramine may increase the excretion rate of Loteprednol etabonate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00180</drugbank-id>
      <name>Flunisolide</name>
      <description>The risk or severity of hypertension can be increased when Flunisolide is combined with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00223</drugbank-id>
      <name>Diflorasone</name>
      <description>The risk or severity of hypertension can be increased when Diflorasone is combined with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00240</drugbank-id>
      <name>Alclometasone</name>
      <description>The risk or severity of hypertension can be increased when Alclometasone is combined with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00253</drugbank-id>
      <name>Medrysone</name>
      <description>The risk or severity of hypertension can be increased when Medrysone is combined with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00288</drugbank-id>
      <name>Amcinonide</name>
      <description>The risk or severity of hypertension can be increased when Amcinonide is combined with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00324</drugbank-id>
      <name>Fluorometholone</name>
      <description>The risk or severity of hypertension can be increased when Fluorometholone is combined with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The risk or severity of hypertension can be increased when Beclomethasone dipropionate is combined with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The risk or severity of hypertension can be increased when Betamethasone is combined with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00547</drugbank-id>
      <name>Desoximetasone</name>
      <description>The risk or severity of hypertension can be increased when Desoximetasone is combined with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The risk or severity of hypertension can be increased when Fluticasone propionate is combined with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone acetonide</name>
      <description>The risk or severity of hypertension can be increased when Fluocinolone acetonide is combined with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00596</drugbank-id>
      <name>Ulobetasol</name>
      <description>The risk or severity of hypertension can be increased when Ulobetasol is combined with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The risk or severity of hypertension can be increased when Triamcinolone is combined with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The risk or severity of hypertension can be increased when Prednisone is combined with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00663</drugbank-id>
      <name>Flumethasone</name>
      <description>The risk or severity of hypertension can be increased when Flumethasone is combined with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>The risk or severity of hypertension can be increased when Fludrocortisone is combined with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The risk or severity of hypertension can be increased when Hydrocortisone is combined with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00764</drugbank-id>
      <name>Mometasone</name>
      <description>The risk or severity of hypertension can be increased when Mometasone is combined with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00838</drugbank-id>
      <name>Clocortolone</name>
      <description>The risk or severity of hypertension can be increased when Clocortolone is combined with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00846</drugbank-id>
      <name>Flurandrenolide</name>
      <description>The risk or severity of hypertension can be increased when Flurandrenolide is combined with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The risk or severity of hypertension can be increased when Prednisolone is combined with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00896</drugbank-id>
      <name>Rimexolone</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Rimexolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Methylprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01013</drugbank-id>
      <name>Clobetasol propionate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Clobetasol propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01047</drugbank-id>
      <name>Fluocinonide</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Fluocinonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01108</drugbank-id>
      <name>Trilostane</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Trilostane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01130</drugbank-id>
      <name>Prednicarbate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Prednicarbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Budesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01260</drugbank-id>
      <name>Desonide</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Desonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01285</drugbank-id>
      <name>Corticotropin</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Corticotropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Cortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Paramethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01410</drugbank-id>
      <name>Ciclesonide</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Ciclesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Aldosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06781</drugbank-id>
      <name>Difluprednate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06786</drugbank-id>
      <name>Halcinonide</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Halcinonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Fluticasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08970</drugbank-id>
      <name>Fluprednidene</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Fluprednidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08971</drugbank-id>
      <name>Fluocortolone</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Fluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Tixocortol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09095</drugbank-id>
      <name>Difluocortolone</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Difluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09378</drugbank-id>
      <name>Fluprednisolone</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Fluprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09383</drugbank-id>
      <name>Meprednisone</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Meprednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11487</drugbank-id>
      <name>Dexamethasone isonicotinate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Dexamethasone isonicotinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11529</drugbank-id>
      <name>Melengestrol</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Melengestrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11750</drugbank-id>
      <name>Clobetasol</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Clobetasol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11921</drugbank-id>
      <name>Deflazacort</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Deflazacort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13003</drugbank-id>
      <name>Cortivazol</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Cortivazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13158</drugbank-id>
      <name>Clobetasone</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Clobetasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13208</drugbank-id>
      <name>Prednylidene</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Prednylidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13223</drugbank-id>
      <name>Fluocortin</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Fluocortin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13491</drugbank-id>
      <name>Fluperolone</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Fluperolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13664</drugbank-id>
      <name>Formocortal</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Formocortal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13728</drugbank-id>
      <name>Halometasone</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Halometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13843</drugbank-id>
      <name>Cloprednol</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Cloprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13856</drugbank-id>
      <name>Fluclorolone</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Fluclorolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Fluticasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14512</drugbank-id>
      <name>Mometasone furoate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Mometasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14538</drugbank-id>
      <name>Hydrocortisone aceponate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Hydrocortisone aceponate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14539</drugbank-id>
      <name>Hydrocortisone acetate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Hydrocortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14540</drugbank-id>
      <name>Hydrocortisone butyrate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Hydrocortisone butyrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14541</drugbank-id>
      <name>Hydrocortisone cypionate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Hydrocortisone cypionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14543</drugbank-id>
      <name>Hydrocortisone probutate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Hydrocortisone probutate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14544</drugbank-id>
      <name>Hydrocortisone valerate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Hydrocortisone valerate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14545</drugbank-id>
      <name>Hydrocortisone succinate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Hydrocortisone succinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00873</drugbank-id>
      <name>Loteprednol</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Loteprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14631</drugbank-id>
      <name>Prednisolone phosphate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Prednisolone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14633</drugbank-id>
      <name>Prednisolone hemisuccinate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Prednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14634</drugbank-id>
      <name>Fluprednidene acetate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Fluprednidene acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14643</drugbank-id>
      <name>Methylprednisolone aceponate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Methylprednisolone aceponate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14644</drugbank-id>
      <name>Methylprednisolone hemisuccinate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Methylprednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14646</drugbank-id>
      <name>Prednisone acetate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Prednisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14652</drugbank-id>
      <name>Clocortolone acetate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Clocortolone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14659</drugbank-id>
      <name>Melengestrol acetate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Melengestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14669</drugbank-id>
      <name>Betamethasone phosphate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Betamethasone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14681</drugbank-id>
      <name>Cortisone</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Cortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15566</drugbank-id>
      <name>Prednisolone acetate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Prednisolone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00357</drugbank-id>
      <name>Aminoglutethimide</name>
      <description>The therapeutic efficacy of Loteprednol etabonate can be decreased when used in combination with Aminoglutethimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00951</drugbank-id>
      <name>Isoniazid</name>
      <description>The serum concentration of Isoniazid can be decreased when it is combined with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The risk or severity of adverse effects can be increased when Loteprednol etabonate is combined with Cyclosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>The risk or severity of adverse effects can be increased when Loteprednol etabonate is combined with Digoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00511</drugbank-id>
      <name>Acetyldigitoxin</name>
      <description>The risk or severity of adverse effects can be increased when Loteprednol etabonate is combined with Acetyldigitoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01078</drugbank-id>
      <name>Deslanoside</name>
      <description>The risk or severity of adverse effects can be increased when Loteprednol etabonate is combined with Deslanoside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>The risk or severity of adverse effects can be increased when Loteprednol etabonate is combined with Digitoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13401</drugbank-id>
      <name>Metildigoxin</name>
      <description>The risk or severity of adverse effects can be increased when Loteprednol etabonate is combined with Metildigoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13467</drugbank-id>
      <name>Lanatoside C</name>
      <description>The risk or severity of adverse effects can be increased when Loteprednol etabonate is combined with Lanatoside C.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13537</drugbank-id>
      <name>Gitoformate</name>
      <description>The risk or severity of adverse effects can be increased when Loteprednol etabonate is combined with Gitoformate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13691</drugbank-id>
      <name>Acetyldigoxin</name>
      <description>The risk or severity of adverse effects can be increased when Loteprednol etabonate is combined with Acetyldigoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04914</drugbank-id>
      <name>G17DT</name>
      <description>The therapeutic efficacy of G17DT can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05144</drugbank-id>
      <name>PEV3A</name>
      <description>The therapeutic efficacy of PEV3A can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05325</drugbank-id>
      <name>INGN 225</name>
      <description>The therapeutic efficacy of INGN 225 can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05374</drugbank-id>
      <name>Rindopepimut</name>
      <description>The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05440</drugbank-id>
      <name>SRP 299</name>
      <description>The therapeutic efficacy of SRP 299 can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05942</drugbank-id>
      <name>GI-5005</name>
      <description>The therapeutic efficacy of GI-5005 can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06400</drugbank-id>
      <name>Vitespen</name>
      <description>The therapeutic efficacy of Vitespen can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06584</drugbank-id>
      <name>TG4010</name>
      <description>The therapeutic efficacy of TG4010 can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09057</drugbank-id>
      <name>Anthrax immune globulin human</name>
      <description>The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10062</drugbank-id>
      <name>Rabies virus inactivated antigen, B</name>
      <description>The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10076</drugbank-id>
      <name>Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen</name>
      <description>The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10276</drugbank-id>
      <name>Rotavirus vaccine</name>
      <description>The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10283</drugbank-id>
      <name>Rabies virus inactivated antigen, A</name>
      <description>The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10317</drugbank-id>
      <name>Rubella virus vaccine</name>
      <description>The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10318</drugbank-id>
      <name>Varicella Zoster Vaccine (Live/attenuated)</name>
      <description>The therapeutic efficacy of Varicella Zoster Vaccine (Live/attenuated) can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10342</drugbank-id>
      <name>Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen</name>
      <description>The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10343</drugbank-id>
      <name>Bacillus calmette-guerin substrain tice live antigen</name>
      <description>The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10583</drugbank-id>
      <name>Clostridium tetani toxoid antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10584</drugbank-id>
      <name>Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10600</drugbank-id>
      <name>Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10769</drugbank-id>
      <name>Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10794</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10803</drugbank-id>
      <name>Typhoid Vi polysaccharide vaccine</name>
      <description>The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10804</drugbank-id>
      <name>Bacillus calmette-guerin substrain connaught live antigen</name>
      <description>The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10805</drugbank-id>
      <name>Yellow Fever Vaccine</name>
      <description>The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10989</drugbank-id>
      <name>Hepatitis A Vaccine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10990</drugbank-id>
      <name>Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen</name>
      <description>The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11003</drugbank-id>
      <name>Anthrax vaccine</name>
      <description>The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11038</drugbank-id>
      <name>Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11040</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11041</drugbank-id>
      <name>Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11044</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11050</drugbank-id>
      <name>Typhoid Vaccine Live</name>
      <description>The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11603</drugbank-id>
      <name>Human rabies virus immune globulin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11627</drugbank-id>
      <name>Hepatitis B Vaccine (Recombinant)</name>
      <description>The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12386</drugbank-id>
      <name>Bacillus calmette-guerin substrain danish 1331 live antigen</name>
      <description>The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12568</drugbank-id>
      <name>Tecemotide</name>
      <description>The therapeutic efficacy of Tecemotide can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13924</drugbank-id>
      <name>Varicella Zoster Vaccine (Recombinant)</name>
      <description>The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14022</drugbank-id>
      <name>Typhoid vaccine</name>
      <description>The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14384</drugbank-id>
      <name>Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14385</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14394</drugbank-id>
      <name>Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen</name>
      <description>The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14409</drugbank-id>
      <name>Human adenovirus e serotype 4 strain cl-68578 antigen</name>
      <description>The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14443</drugbank-id>
      <name>Vibrio cholerae CVD 103-HgR strain live antigen</name>
      <description>The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14445</drugbank-id>
      <name>Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14449</drugbank-id>
      <name>Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen</name>
      <description>The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14619</drugbank-id>
      <name>Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14620</drugbank-id>
      <name>Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14685</drugbank-id>
      <name>Adenovirus type 7 vaccine live</name>
      <description>The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14711</drugbank-id>
      <name>Vaccinia virus strain new york city board of health live antigen</name>
      <description>The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15274</drugbank-id>
      <name>Pertussis vaccine</name>
      <description>The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15461</drugbank-id>
      <name>Yersinia pestis 195/p antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15483</drugbank-id>
      <name>Modified vaccinia ankara</name>
      <description>The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01364</drugbank-id>
      <name>Ephedrine</name>
      <description>Ephedrine may increase the excretion rate of Loteprednol etabonate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00030</drugbank-id>
      <name>Insulin human</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00046</drugbank-id>
      <name>Insulin lispro</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Insulin lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00047</drugbank-id>
      <name>Insulin glargine</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Insulin glargine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00071</drugbank-id>
      <name>Insulin pork</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00197</drugbank-id>
      <name>Troglitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Troglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00222</drugbank-id>
      <name>Glimepiride</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Glimepiride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00263</drugbank-id>
      <name>Sulfisoxazole</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Sulfisoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Disopyramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00284</drugbank-id>
      <name>Acarbose</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Acarbose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00331</drugbank-id>
      <name>Metformin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Metformin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00359</drugbank-id>
      <name>Sulfadiazine</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Sulfadiazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Rosiglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00414</drugbank-id>
      <name>Acetohexamide</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Acetohexamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Quinine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00491</drugbank-id>
      <name>Miglitol</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Miglitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Chlorpropamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Nateglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Pentamidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Mifepristone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Tolazamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00912</drugbank-id>
      <name>Repaglinide</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Repaglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00914</drugbank-id>
      <name>Phenformin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Phenformin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Sulfamethoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Glyburide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Glipizide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01120</drugbank-id>
      <name>Gliclazide</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Gliclazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Tolbutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01132</drugbank-id>
      <name>Pioglitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Pioglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Bromocriptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01251</drugbank-id>
      <name>Gliquidone</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Gliquidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01252</drugbank-id>
      <name>Mitiglinide</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Mitiglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Sitagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Sunitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01276</drugbank-id>
      <name>Exenatide</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Exenatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01277</drugbank-id>
      <name>Mecasermin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Mecasermin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01278</drugbank-id>
      <name>Pramlintide</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Pramlintide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01289</drugbank-id>
      <name>Glisoxepide</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Glisoxepide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01306</drugbank-id>
      <name>Insulin aspart</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Insulin aspart.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01307</drugbank-id>
      <name>Insulin detemir</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Insulin detemir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01309</drugbank-id>
      <name>Insulin glulisine</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Insulin glulisine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01382</drugbank-id>
      <name>Glymidine</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Glymidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01700</drugbank-id>
      <name>AICA ribonucleotide</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with AICA ribonucleotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04830</drugbank-id>
      <name>Buformin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Buformin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04876</drugbank-id>
      <name>Vildagliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Vildagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04878</drugbank-id>
      <name>Voglibose</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Voglibose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05115</drugbank-id>
      <name>NN344</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with NN344.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05819</drugbank-id>
      <name>NBI-6024</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with NBI-6024.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06011</drugbank-id>
      <name>AMG-222</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with AMG-222.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06127</drugbank-id>
      <name>Bisegliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Bisegliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06203</drugbank-id>
      <name>Alogliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Alogliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Dapagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06335</drugbank-id>
      <name>Saxagliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Saxagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06655</drugbank-id>
      <name>Liraglutide</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Liraglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08382</drugbank-id>
      <name>Gosogliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Gosogliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Linagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Canagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08962</drugbank-id>
      <name>Glibornuride</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Glibornuride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09022</drugbank-id>
      <name>Benfluorex</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Benfluorex.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Empagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09043</drugbank-id>
      <name>Albiglutide</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Albiglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09045</drugbank-id>
      <name>Dulaglutide</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Dulaglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09198</drugbank-id>
      <name>Lobeglitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Lobeglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09199</drugbank-id>
      <name>Netoglitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Netoglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09200</drugbank-id>
      <name>Rivoglitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Rivoglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09201</drugbank-id>
      <name>Ciglitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Ciglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09265</drugbank-id>
      <name>Lixisenatide</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Lixisenatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09456</drugbank-id>
      <name>Insulin beef</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Insulin beef.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09564</drugbank-id>
      <name>Insulin degludec</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Insulin degludec.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11567</drugbank-id>
      <name>Insulin peglispro</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Insulin peglispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11568</drugbank-id>
      <name>Insulin tregopil</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Insulin tregopil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11698</drugbank-id>
      <name>Ipragliflozin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Ipragliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11723</drugbank-id>
      <name>Dutogliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Dutogliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11780</drugbank-id>
      <name>Allicin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Allicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11824</drugbank-id>
      <name>Tofogliflozin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Tofogliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11827</drugbank-id>
      <name>Ertugliflozin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Ertugliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11898</drugbank-id>
      <name>2,4-thiazolidinedione</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with 2,4-thiazolidinedione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11936</drugbank-id>
      <name>Bempedoic acid</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Bempedoic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11950</drugbank-id>
      <name>Teneligliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Teneligliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11992</drugbank-id>
      <name>Omarigliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Omarigliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12268</drugbank-id>
      <name>Carmegliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Carmegliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12412</drugbank-id>
      <name>Gemigliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Gemigliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12417</drugbank-id>
      <name>Anagliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Anagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12625</drugbank-id>
      <name>Evogliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Evogliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12713</drugbank-id>
      <name>Sotagliflozin</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Sotagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12781</drugbank-id>
      <name>Balaglitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Balaglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12935</drugbank-id>
      <name>Remogliflozin etabonate</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Remogliflozin etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13406</drugbank-id>
      <name>Carbutamide</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Carbutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13446</drugbank-id>
      <name>Guar gum</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Guar gum.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13675</drugbank-id>
      <name>Metahexamide</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Metahexamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13928</drugbank-id>
      <name>Semaglutide</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Semaglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14027</drugbank-id>
      <name>Taspoglutide</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Taspoglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14035</drugbank-id>
      <name>Englitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Englitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15171</drugbank-id>
      <name>Tirzepatide</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Tirzepatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15217</drugbank-id>
      <name>Gastric inhibitory polypeptide</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Gastric inhibitory polypeptide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06119</drugbank-id>
      <name>Cenobamate</name>
      <description>The serum concentration of Loteprednol etabonate can be decreased when it is combined with Cenobamate.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>3.08</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.8</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>6.93e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.94</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>chloromethyl (1R,3aS,3bS,9aR,9bS,10S,11aS)-1-[(ethoxycarbonyl)oxy]-10-hydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-1-carboxylate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>loteprednol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>466.96</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>466.175831</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[H][C@@]12CC[C@](OC(=O)OCC)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C24H31ClO7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C24H31ClO7/c1-4-30-21(29)32-24(20(28)31-13-25)10-8-17-16-6-5-14-11-15(26)7-9-22(14,2)19(16)18(27)12-23(17,24)3/h7,9,11,16-19,27H,4-6,8,10,12-13H2,1-3H3/t16-,17-,18-,19+,22-,23-,24-/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>DMKSVUSAATWOCU-HROMYWEYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>99.13</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>118.17</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>48.43</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>14.88</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-2.9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>5 mg/mL</value>
      <source/>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>220-224 °C</value>
      <source/>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.4</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>20429</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>31784</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>9865442</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46504713</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D01689</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>392049</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164764569</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001045</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Loteprednol</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1200865</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic2/lotemax.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/international/loteprednol.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB14596</drugbank-id>
        <name>Loteprednol etabonate</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02133</drugbank-id>
        <name>Δ1-cortienic acid etabonate (PJ-91)</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0000930</drugbank-id>
          <name>Serum paraoxonase/arylesterase 1</name>
          <uniprot-id>P27169</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DBMET02133</drugbank-id>
        <name>Δ1-cortienic acid etabonate (PJ-91)</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02134</drugbank-id>
        <name>Δ1-cortienic acid (PJ-90)</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0000930</drugbank-id>
          <name>Serum paraoxonase/arylesterase 1</name>
          <uniprot-id>P27169</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
  </reactions>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000794</id>
      <name>Glucocorticoid receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A10906</ref-id>
            <pubmed-id>2004037</pubmed-id>
            <citation>Druzgala P, Hochhaus G, Bodor N: Soft drugs--10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. J Steroid Biochem Mol Biol. 1991 Feb;38(2):149-54.</citation>
          </article>
          <article>
            <ref-id>A10907</ref-id>
            <pubmed-id>17020532</pubmed-id>
            <citation>Bodor N, Buchwald P: Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of soft corticosteroids. Curr Pharm Des. 2006;12(25):3241-60.</citation>
          </article>
          <article>
            <ref-id>A10908</ref-id>
            <pubmed-id>12861354</pubmed-id>
            <citation>Szelenyi I, Hochhaus G, Heer S, Kusters S, Marx D, Poppe H, Engel J: Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways. Drugs Today (Barc). 2000 May;36(5):313-20.</citation>
          </article>
          <article>
            <ref-id>A10909</ref-id>
            <pubmed-id>15684812</pubmed-id>
            <citation>Samudre SS, Lattanzio FA Jr, Williams PB, Sheppard JD Jr: Comparison of topical steroids for acute anterior uveitis. J Ocul Pharmacol Ther. 2004 Dec;20(6):533-47.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P04150" source="Swiss-Prot">
        <name>Glucocorticoid receptor</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth. Involved in chromatin remodeling. May play a negative role in adipogenesis through the regulation of lipolytic and antilipogenic genes expression.</specific-function>
        <gene-name>NR3C1</gene-name>
        <locus>5q31.3</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.31</theoretical-pi>
        <molecular-weight>85658.57</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:7978</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>NR3C1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X03225</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>31680</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>625</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>625</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P04150</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GCR_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GR</synonym>
          <synonym>GRL</synonym>
          <synonym>Nuclear receptor subfamily 3 group C member 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001584|Glucocorticoid receptor
MDSKESLTPGREENPSSVLAQERGDVMDFYKTLRGGATVKVSASSPSLAVASQSDSKQRR
LLVDFPKGSVSNAQQPDLSKAVSLSMGLYMGETETKVMGNDLGFPQQGQISLSSGETDLK
LLEESIANLNRSTSVPENPKSSASTAVSAAPTEKEFPKTHSDVSSEQQHLKGQTGTNGGN
VKLYTTDQSTFDILQDLEFSSGSPGKETNESPWRSDLLIDENCLLSPLAGEDDSFLLEGN
SNEDCKPLILPDTKPKIKDNGDLVLSSPSNVTLPQVKTEKEDFIELCTPGVIKQEKLGTV
YCQASFPGANIIGNKMSAISVHGVSTSGGQMYHYDMNTASLSQQQDQKPIFNVIPPIPVG
SENWNRCQGSGDDNLTSLGTLNFPGRTVFSNGYSSPSMRPDVSSPPSSSSTATTGPPPKL
CLVCSDEASGCHYGVLTCGSCKVFFKRAVEGQHNYLCAGRNDCIIDKIRRKNCPACRYRK
CLQAGMNLEARKTKKKIKGIQQATTGVSQETSENPGNKTIVPATLPQLTPTLVSLLEVIE
PEVLYAGYDSSVPDSTWRIMTTLNMLGGRQVIAAVKWAKAIPGFRNLHLDDQMTLLQYSW
MFLMAFALGWRSYRQSSANLLCFAPDLIINEQRMTLPCMYDQCKHMLYVSSELHRLQVSY
EEYLCMKTLLLLSSVPKDGLKSQELFDEIRMTYIKELGKAIVKREGNSSQNWQRFYQLTK
LLDSMHEVVENLLNYCFQTFLDKTMSIEFPEMLAEIITNQIPKYSNGNIKKLLFHQK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020486|Glucocorticoid receptor (NR3C1)
ATGGACTCCAAAGAATCATTAACTCCTGGTAGAGAAGAAAACCCCAGCAGTGTGCTTGCT
CAGGAGAGGGGAGATGTGATGGACTTCTATAAAACCCTAAGAGGAGGAGCTACTGTGAAG
GTTTCTGCGTCTTCACCCTCACTGGCTGTCGCTTCTCAATCAGACTCCAAGCAGCGAAGA
CTTTTGGTTGATTTTCCAAAAGGCTCAGTAAGCAATGCGCAGCAGCCAGATCTGTCCAAA
GCAGTTTCACTCTCAATGGGACTGTATATGGGAGAGACAGAAACAAAAGTGATGGGAAAT
GACCTGGGATTCCCACAGCAGGGCCAAATCAGCCTTTCCTCGGGGGAAACAGACTTAAAG
CTTTTGGAAGAAAGCATTGCAAACCTCAATAGGTCGACCAGTGTTCCAGAGAACCCCAAG
AGTTCAGCATCCACTGCTGTGTCTGCTGCCCCCACAGAGAAGGAGTTTCCAAAAACTCAC
TCTGATGTATCTTCAGAACAGCAACATTTGAAGGGCCAGACTGGCACCAACGGTGGCAAT
GTGAAATTGTATACCACAGACCAAAGCACCTTTGACATTTTGCAGGATTTGGAGTTTTCT
TCTGGGTCCCCAGGTAAAGAGACGAATGAGAGTCCTTGGAGATCAGACCTGTTGATAGAT
GAAAACTGTTTGCTTTCTCCTCTGGCGGGAGAAGACGATTCATTCCTTTTGGAAGGAAAC
TCGAATGAGGACTGCAAGCCTCTCATTTTACCGGACACTAAACCCAAAATTAAGGATAAT
GGAGATCTGGTTTTGTCAAGCCCCAGTAATGTAACACTGCCCCAAGTGAAAACAGAAAAA
GAAGATTTCATCGAACTCTGCACCCCTGGGGTAATTAAGCAAGAGAAACTGGGCACAGTT
TACTGTCAGGCAAGCTTTCCTGGAGCAAATATAATTGGTAATAAAATGTCTGCCATTTCT
GTTCATGGTGTGAGTACCTCTGGAGGACAGATGTACCACTATGACATGAATACAGCATCC
CTTTCTCAACAGCAGGATCAGAAGCCTATTTTTAATGTCATTCCACCAATTCCCGTTGGT
TCCGAAAATTGGAATAGGTGCCAAGGATCTGGAGATGACAACTTGACTTCTCTGGGGACT
CTGAACTTCCCTGGTCGAACAGTTTTTTCTAATGGCTATTCAAGCCCCAGCATGAGACCA
GATGTAAGCTCTCCTCCATCCAGCTCCTCAACAGCAACAACAGGACCACCTCCCAAACTC
TGCCTGGTGTGCTCTGATGAAGCTTCAGGATGTCATTATGGAGTCTTAACTTGTGGAAGC
TGTAAAGTTTTCTTCAAAAGAGCAGTGGAAGGACAGCACAATTACCTATGTGCTGGAAGG
AATGATTGCATCATCGATAAAATTCGAAGAAAAAACTGCCCAGCATGCCGCTATCGAAAA
TGTCTTCAGGCTGGAATGAACCTGGAAGCTCGAAAAACAAAGAAAAAAATAAAAGGAATT
CAGCAGGCCACTACAGGAGTCTCACAAGAAACCTCTGAAAATCCTGGTAACAAAACAATA
GTTCCTGCAACGTTACCACAACTCACCCCTACCCTGGTGTCACTGTTGGAGGTTATTGAA
CCTGAAGTGTTATATGCAGGATATGATAGCTCTGTTCCAGACTCAACTTGGAGGATCATG
ACTACGCTCAACATGTTAGGAGGGCGGCAAGTGATTGCAGCAGTGAAATGGGCAAAGGCA
ATACCAGGTTTCAGGAACTTACACCTGGATGACCAAATGACCCTACTGCAGTACTCCTGG
ATGTTTCTTATGGCATTTGCTCTGGGGTGGAGATCATATAGACAATCAAGTGCAAACCTG
CTGTGTTTTGCTCCTGATCTGATTATTAATGAGCAGAGAATGACTCTACCCTGCATGTAC
GACCAATGTAAACACATGCTGTATGTTTCCTCTGAGTTACACAGGCTTCAGGTATCTTAT
GAAGAGTATCTCTGTATGAAAACCTTACTGCTTCTCTCTTCAGTTCCTAAGGACGGTCTG
AAGAGCCAAGAGCTATTTGATGAAATTAGAATGACCTACATCAAAGAGCTAGGAAAAGCC
ATTGTCAAGAGGGAAGGAAACTCCAGCCAGAACTGGCAGCGGTTTTATCAACTGACAAAA
CTCTTGGATTCTATGCATGAAGTGGTTGAAAATCTCCTTAACTATTGCTTCCAAACATTT
TTGGATAAGACCATGAGTATTGAATTCCCCGAGATGTTAGCTGAAATCATCACCAATCAG
ATACCAAAATATTCAAATGGAAATATCAAAAAACTTCTGTTTCATCAAAAGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00104</identifier>
            <name>Hormone_recep</name>
          </pfam>
          <pfam>
            <identifier>PF00105</identifier>
            <name>zf-C4</name>
          </pfam>
          <pfam>
            <identifier>PF02155</identifier>
            <name>GCR</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial matrix</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glucocorticoid receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glucocorticoid-activated RNA polymerase II transcription factor binding transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II core promoter proximal region sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hormone binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor activity, sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to steroid hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chromatin modification</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription, DNA-templated</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="1">
      <id>BE0002638</id>
      <name>Cytochrome P450 3A4</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L3850</ref-id>
            <title>NCI/NIH</title>
            <url>https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&amp;version=18.06d&amp;code=C72818&amp;ns=ncit&amp;type=relationship&amp;key=null&amp;b=1&amp;n=0&amp;vse=null</url>
          </link>
          <link>
            <ref-id>L4539</ref-id>
            <title>Electronic Medicines Compendium: Loteprednol etabonate Monograph</title>
            <url>https://www.medicines.org.uk/emc/product/6212</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08684" source="Swiss-Prot">
        <name>Cytochrome P450 3A4</name>
        <general-function>Vitamin d3 25-hydroxylase activity</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide (PubMed:11159812). Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro (PubMed:21576599).</specific-function>
        <gene-name>CYP3A4</gene-name>
        <locus>7q21.1</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions>2-22</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.25</theoretical-pi>
        <molecular-weight>57342.67</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2637</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP3A4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M18907</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1337</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08684</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP3A4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1,8-cineole 2-exo-monooxygenase</synonym>
          <synonym>1.14.13.-</synonym>
          <synonym>Albendazole monooxygenase</synonym>
          <synonym>Albendazole sulfoxidase</synonym>
          <synonym>Cholesterol 25-hydroxylase</synonym>
          <synonym>CYP3A3</synonym>
          <synonym>CYPIIIA3</synonym>
          <synonym>CYPIIIA4</synonym>
          <synonym>Cytochrome P450 3A3</synonym>
          <synonym>Cytochrome P450 HLp</synonym>
          <synonym>Cytochrome P450 NF-25</synonym>
          <synonym>Cytochrome P450-PCN1</synonym>
          <synonym>Nifedipine oxidase</synonym>
          <synonym>Quinine 3-monooxygenase</synonym>
          <synonym>Taurochenodeoxycholate 6-alpha-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021936|Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021937|Cytochrome P450 3A4 (CYP3A4)
ATGGCTCTCATCCCAGACTTGGCCATGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG
CTCCTCTATCTATATGGAACCCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG
CCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT
GACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT
GTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT
GTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA
GCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA
AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG
AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC
ATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA
GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT
CTCTCAATAATCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTGTTT
CCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGCCTC
GAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAATTCA
AAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATTATC
TTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAACTG
GCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCCAAT
AAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTGAAT
GAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGATGTT
GAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCTCTT
CACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGCAAG
AAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGAAAC
TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG
AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGAGGA
CTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTAAGT
GGAGCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>albendazole monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>quinine 3-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>taurochenodeoxycholate 6alpha-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>testosterone 6-beta-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vitamin D 24-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vitamin D3 25-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>androgen metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcitriol biosynthetic process from calciol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin D metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="2">
      <id>BE0000930</id>
      <name>Serum paraoxonase/arylesterase 1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A38681</ref-id>
            <pubmed-id>28017774</pubmed-id>
            <citation>Samir A, Bodor N, Imai T: Identification of esterase involved in the metabolism of two corticosteroid soft drugs. Biochem Pharmacol. 2017 Mar 1;127:82-89. doi: 10.1016/j.bcp.2016.12.010. Epub 2016 Dec 22.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P27169" source="Swiss-Prot">
        <name>Serum paraoxonase/arylesterase 1</name>
        <general-function>Protein homodimerization activity</general-function>
        <specific-function>Hydrolyzes the toxic metabolites of a variety of organophosphorus insecticides. Capable of hydrolyzing a broad spectrum of organophosphate substrates and lactones, and a number of aromatic carboxylic acid esters. Mediates an enzymatic protection of low density lipoproteins against oxidative modification and the consequent series of events leading to atheroma formation.</specific-function>
        <gene-name>PON1</gene-name>
        <locus>7q21.3</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>2-</signal-regions>
        <theoretical-pi>4.89</theoretical-pi>
        <molecular-weight>39730.99</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9204</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PON1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M63012</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>190192</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P27169</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PON1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.1.2</synonym>
          <synonym>A-esterase 1</synonym>
          <synonym>Aromatic esterase 1</synonym>
          <synonym>K-45</synonym>
          <synonym>PON</synonym>
          <synonym>PON 1</synonym>
          <synonym>Serum aryldialkylphosphatase 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0020496|Serum paraoxonase/arylesterase 1
MAKLIALTLLGMGLALFRNHQSSYQTRLNALREVQPVELPNCNLVKGIETGSEDLEILPN
GLAFISSGLKYPGIKSFNPNSPGKILLMDLNEEDPTVLELGITGSKFDVSSFNPHGISTF
TDEDNAMYLLVVNHPDAKSTVELFKFQEEEKSLLHLKTIRHKLLPNLNDIVAVGPEHFYG
TNDHYFLDPYLQSWEMYLGLAWSYVVYYSPSEVRVVAEGFDFANGINISPDGKYVYIAEL
LAHKIHVYEKHANWTLTPLKSLDFNTLVDNISVDPETGDLWVGCHPNGMKIFFYDSENPP
ASEVLRIQNILTEEPKVTQVYAENGTVLQGSTVASVYKGKLLIGTVFHKALYCEL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020497|Serum paraoxonase/arylesterase 1 (PON1)
ATGGCGAAGCTGATTGCGCTCACCCTCTTGGGGATGGGACTGGCACTCTTCAGGAACCAC
CAGTCTTCTTACCAAACACGACTTAATGCTCTCCGAGAGGTACAACCCGTAGAACTTCCT
AACTGTAATTTAGTTAAAGGAATCGAAACTGGCTCTGAAGACTTGGAGATACTGCCTAAT
GGACTGGCTTTCATTAGCTCTGGATTAAAGTATCCTGGAATAAAGAGCTTCAACCCCAAC
AGTCCTGGAAAAATACTTCTGATGGACCTGAATGAAGAAGATCCAACAGTGTTGGAATTG
GGGATCACTGGAAGTAAATTTGATGTATCTTCATTTAACCCTCATGGGATTAGCACATTC
ACAGATGAAGATAATGCCATGTACCTCCTGGTGGTGAACCATCCAGATGCCAAGTCCACA
GTGGAGTTGTTTAAATTTCAAGAAGAAGAAAAATCGCTTTTGCATCTAAAAACCATCAGA
CATAAACTTCTGCCTAATTTGAATGATATTGTTGCTGTGGGACCTGAGCACTTTTATGGC
ACAAATGATCACTATTTTCTTGACCCCTACTTACAATCCTGGGAGATGTATTTGGGTTTA
GCGTGGTCGTATGTTGTCTACTATAGTCCAAGTGAAGTTCGAGTGGTGGCAGAAGGATTT
GATTTTGCTAATGGAATCAACATTTCACCCGATGGCAAGTATGTCTATATAGCTGAGTTG
CTGGCTCATAAGATTCATGTGTATGAAAAGCATGCTAATTGGACTTTAACTCCATTGAAG
TCCCTTGACTTTAATACCCTCGTGGATAACATATCTGTGGATCCTGAGACAGGAGACCTT
TGGGTTGGATGCCATCCCAATGGCATGAAAATCTTCTTCTATGACTCAGAGAATCCTCCT
GCATCAGAGGTGCTTCGAATCCAGAACATTCTAACAGAAGAACCTAAAGTGACACAGGTT
TATGCAGAAAATGGCACAGTGTTGCAAGGCAGTACAGTTGCCTCTGTGTACAAAGGGAAA
CTGCTGATTGGCACAGTGTTTCACAAAGCTCTTTACTGTGAGCTCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01731</identifier>
            <name>Arylesterase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>high-density lipoprotein particle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>spherical high-density lipoprotein particle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aryldialkylphosphatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arylesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phospholipid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aromatic compound catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>carboxylic acid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dephosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organophosphate catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylcholine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cholesterol efflux</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to external stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to fatty acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to fluoride</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nutrient levels</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to toxic substance</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>